MTOR and neoplasm: Inhibition of SCD1 can limit the growth of tumor cells, and the combination of SCD1 inhibitors with mTOR inhibitors may have an inhibitory effect on lipid metabolism in renal cancer, which may lead to a new therapeutic approach 191.